• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Report: 20,000 COVID cases traced to Boston medtech company’s conference

Report: 20,000 COVID cases traced to Boston medtech company’s conference

August 25, 2020 By Sean Whooley

BiogenThe “super-spreading” event held by Biogen (NSDQ:BIIB) in February reportedly led to approximately 20,000 COVID-19 cases across four Massachusetts counties.

According to a Boston Globe report, the international company meeting at the Marriott Long Wharf hotel in Boston was said to have resulted in 99 identified cases of the virus, but, according to scientists studying early cases, that number reached roughly 20,000 by early May in those four counties.

Researchers studied all confirmed early cases of COVID-19 in the area by changes in the genetic makeup of coronaviruses to gauge the spread of the event hosted by Cambridge, Mass.-based Biogen, according to The Globe.

Almost all of the 772 cases observed came from Essex, Middlesex, Norfolk and Suffolk counties. Through observing mutations in the genetic code of the viruses, the researchers identified more than 80 distinct SARS-CoV-2 genomes that spread around the Boston area, the report says.

The researchers found that 289 of the 772 cases had one unique genetic signature traceable to the meeting Biogen held on Feb. 26 and Feb. 27. Of those 289 cases, the study says 122 were people living in Boston-area homeless shelters and employees who work at those shelters.

The report states that the study has not yet been peer-reviewed for publication, but the researchers claim that their estimate was garnered based on viruses isolated from 772 local patients.

Harvard T.H. Chan School of Public Health professor of epidemiology Caroline Buckee, who was not among the study’s researchers, told the newspaper that she found the estimate from the study to be believable.

“Super-spreading is really a key component of how we ended up with an epidemic of this gravity,” Buckee told The Globe. “If you think about it, all the cases in the whole world originated from one case. That’s the nature of the exponential growth of epidemics.”

When the Biogen conference took place, the understanding of the virus was far more limited than it is today, as a number of safety measures have been put in place across the globe in an effort to combat the virus, which has led to more than 176,000 deaths in the U.S. so far. However, in a statement to The Globe, Biogen did not dispute the study or the researchers’ estimates.

“We never would have knowingly put anyone at risk,” Biogen told The Globe. “When we learned a number of our colleagues were ill, we did not know the cause was COVID-19, but we immediately notified public health authorities and took steps to limit the spread.”

Filed Under: Business/Financial News, Featured Tagged With: Biogen, Boston, coronavirus, COVID-19

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy